CA Patent

CA2824092C — Use of alk inhibitors for the treatment of eml4-alk+ non-small cell lung cancer

Assigned to Novartis AG · Expires 2020-06-30 · 6y expired

What this patent protects

The invention pertains to the use of compounds of Formula (I) for treating non-small cell lung cancer: (see formula I).

USPTO Abstract

The invention pertains to the use of compounds of Formula (I) for treating non-small cell lung cancer: (see formula I).

Drugs covered by this patent

Patent Metadata

Patent number
CA2824092C
Jurisdiction
CA
Classification
—
Expires
2020-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.